Abstract
Primary biliary cholangitis is a progressive, autoimmune disease of the interlobular bile ducts, leading to secondary damage of hepatocytes that may progress to cirrhosis and liver failure. Until recently, the only approved treatment was ursodeoxycholic acid. However, 40% of patients do not have an adequate response. Obeticholic acid was approved for treatment as add-on therapy in this group of patients. Off-label use of fibrates has also been reported to be effective. Several new therapies are in development and may further add to the treatment options available to patients with primary biliary cholangitis.
| Original language | English (US) |
|---|---|
| Journal | Clinics in Liver Disease |
| DOIs | |
| State | Accepted/In press - Jan 1 2018 |
Fingerprint
Keywords
- Autoimmune liver disease
- Bile acids
- Farnesoid X receptor
- Therapy
ASJC Scopus subject areas
- Hepatology
Cite this
Current Treatment Options for Primary Biliary Cholangitis. / Wong, Kimberly A.; Bahar, Runalia; Liu, Chung H.; Bowlus, Christopher.
In: Clinics in Liver Disease, 01.01.2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Current Treatment Options for Primary Biliary Cholangitis
AU - Wong, Kimberly A.
AU - Bahar, Runalia
AU - Liu, Chung H.
AU - Bowlus, Christopher
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Primary biliary cholangitis is a progressive, autoimmune disease of the interlobular bile ducts, leading to secondary damage of hepatocytes that may progress to cirrhosis and liver failure. Until recently, the only approved treatment was ursodeoxycholic acid. However, 40% of patients do not have an adequate response. Obeticholic acid was approved for treatment as add-on therapy in this group of patients. Off-label use of fibrates has also been reported to be effective. Several new therapies are in development and may further add to the treatment options available to patients with primary biliary cholangitis.
AB - Primary biliary cholangitis is a progressive, autoimmune disease of the interlobular bile ducts, leading to secondary damage of hepatocytes that may progress to cirrhosis and liver failure. Until recently, the only approved treatment was ursodeoxycholic acid. However, 40% of patients do not have an adequate response. Obeticholic acid was approved for treatment as add-on therapy in this group of patients. Off-label use of fibrates has also been reported to be effective. Several new therapies are in development and may further add to the treatment options available to patients with primary biliary cholangitis.
KW - Autoimmune liver disease
KW - Bile acids
KW - Farnesoid X receptor
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=85047222695&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047222695&partnerID=8YFLogxK
U2 - 10.1016/j.cld.2018.03.003
DO - 10.1016/j.cld.2018.03.003
M3 - Article
C2 - 30259848
AN - SCOPUS:85047222695
JO - Clinics in Liver Disease
JF - Clinics in Liver Disease
SN - 1089-3261
ER -